Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) and Plus Therapeutics (NASDAQ:PSTV) Financial Comparison

Plus Therapeutics (NASDAQ:PSTV) and Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Valuation and Earnings

This table compares Plus Therapeutics and Inspira Technologies Oxy B.H.N.”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Plus Therapeutics	$4.91 million	1.41	-$13.32 million	($3.16)	-0.37
Inspira Technologies Oxy B.H.N.	N/A	N/A	-$11.29 million	N/A	N/A

Inspira Technologies Oxy B.H.N. has lower revenue, but higher earnings than Plus Therapeutics.

Volatility and Risk

Plus Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Inspira Technologies Oxy B.H.N. has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500.

Profitability

This table compares Plus Therapeutics and Inspira Technologies Oxy B.H.N.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Plus Therapeutics	-240.15%	N/A	-127.52%
Inspira Technologies Oxy B.H.N.	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and target prices for Plus Therapeutics and Inspira Technologies Oxy B.H.N., as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Plus Therapeutics	0	0	2	0	3.00
Inspira Technologies Oxy B.H.N.	0	0	0	0	0.00

Plus Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 1,096.58%. Given Plus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Inspira Technologies Oxy B.H.N..

Insider & Institutional Ownership

3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Inspira Technologies Oxy B.H.N. shares are owned by institutional investors. 5.5% of Plus Therapeutics shares are owned by company insiders. Comparatively, 29.4% of Inspira Technologies Oxy B.H.N. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Inspira Technologies Oxy B.H.N. beats Plus Therapeutics on 6 of the 10 factors compared between the two stocks.

About Plus Therapeutics

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.